Ro-3306

Catalog No.S7747

Molecular Weight(MW): 351.45

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

Cited by 4 Publications

Nature, 2016, 539(7627):54-58

PubMed: 27760120

J Cell Biol, 2015, 209(2):221-34

PubMed: 25918224

Arthritis Rheumatol , 2016, 68(5):1222-32

PubMed: 26663909

Sci Rep, 2017, 7:41950

PubMed: 28176818

3 Customer Reviews

HeLa cells were untreated or treated with either colcemid (10 μg/ml for 16 h), RO-3306 (9 μM for 16 h), or both colcemid and RO-3306, as indicated. Cells were then lysed, and proteins were detected by Western analysis.

J Cell Biol, 2015, 209(2): 221-34 . Ro-3306 purchased from Selleck.

A, Expression of IFIT3 in HeLa cells pretreated with 5 μM RO-3306 for 12 hours and then stimulated with type I IFN (1,000 units/ml) for 8 hours. The cells were collected and total RNA was extracted for the detection of IFIT3 mRNA. Results are the relative expression levels of IFIT3 mRNA normalized to endogenous GAPDH mRNA levels. B, Expression of IFI27 in HeLa cells measured in the same samples as in A.

Arthritis Rheumatol, 2016, 68(5):1222-32.. Ro-3306 purchased from Selleck.
AML cells were treated with AZ20 in the absence or presence of RO-3306 (RO) for 24 h. Cells were then subjected to annexin V-FITC/PI staining and flow cytometry analyses. Combined treatment was compared to AZ20 treatment alone using pair-wise two-sample t-test. ***Indicates p < 0.001.

Sci Rep, 2017, 7:41950. Ro-3306 purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

Targets

CDK1 ^[1] (Cell-free assay)	PKCδ ^[1] (Cell-free assay)	SGK ^[1] (Cell-free assay)	ERK ^[1] (Cell-free assay)
20 nM(Ki)	318 nM(Ki)	497 nM(Ki)	1980 nM(Ki)

In vitro

RO-3306 inhibits CDK1/cyclin B1, CDK1/cyclin A, CDK2/cyclin E, and CDK4/cyclin D activity with Ki of 35 nM, 110 nM, 340 nM, and over 2000 nM, respectively. Treatment of HCT116, SW480, and HeLa cells with RO-3306 for 20 h leads to a complete block of the cell cycle in the G2/M phase. The proliferation of both HCT116 and SW480 is effectively blocked by RO-3306. RO-3306 appears to be more proapoptotic in cancer cells (HCT116 and SW480) than nontumorigenic cells (MCF 10A and MCF 12A).^[1] RO-3306 effectively arrests oocyte maturation at a concentration of 10 μM.^[2]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
human NCI-SNU-1 cell	NEHuXWhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M33Zb2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLWPOWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC55M{C5OUDPxE1?	MlTPV2FPT0WU
human H460a cells	MVrQdo9tcW[ncnH0bY9vKGG\|c3H5		M2ntUmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSES2NIEh[2WubIOsJGlEPTB;MT6wOEDPxE1?	M3v0elE4OzB\|NEKx
human MDA435 cells	MnTsVJJwdGmoZYLheIlwdiCjc4PhfS=>		NX;F[GtPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGE1OzViY3XscJMtKEmFNUC9NU4yPCEQvF2=	NX3sO\|E3OTd\|MEO0NlE>
human HCT116 cells	MWDQdo9tcW[ncnH0bY9vKGG\|c3H5		MknKRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOsJGlEPTB;MT6xOEDPxE1?	MnriNVc{ODN2MkG=
human H4 cell	NHXIendIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXnGXpBPUW6qaXLpeIlwdiCxZjDoeY1idiCKNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNVU5PzVizszN	M2TJVHNCVkeHUh?=
human PA-1 cell	MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NF\kR2RKdmirYnn0bY9vKG:oIHj1cYFvKFCDLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlIzPjV2IN88US=>	NXnQbo9JW0GQR1XS
human T98G cell	NHOzSotIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NWrvNmRqUW6qaXLpeIlwdiCxZjDoeY1idiCWOUjHJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4{PjhzMjFOwG0>	NFL4[WdUSU6JRWK=
human SW1710 cell	MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MYTJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOlE1ODhizszN	MWPTRW5ITVJ?
human U251 cell	MkjRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVnSOndpUW6qaXLpeIlwdiCxZjDoeY1idiCXMkWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43Ozd5MTFOwG0>	MV\TRW5ITVJ?
human ALL-PO cell	NE\PPIlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVLJcohq[mm2aX;uJI9nKGi3bXHuJGFNVC2STzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H589yNKEmFNUC9NU46ODhzMzFOwG0>	NUT5[GhXW0GQR1XS
human RKO cells	MWXQdo9tcW[ncnH0bY9vKGG\|c3H5		MknwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCUS1:gZ4VtdHNuIFnDOVA:OiEQvF2=	MlTaNVc{ODN2MkG=
human SK-N-DZ cell	MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4rXfGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTj3EXkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvODF6N{[g{txO	MVfTRW5ITVJ?
human A4-Fuk cell	NWrQZm1CT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MnnITY5pcWKrdHnvckBw\iCqdX3hckBCPC2IdXugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlA2PjB2IN88US=>	NEfLcG5USU6JRWK=
human SW480 cells	NULJ[XdNWHKxbHnm[ZJifGmxbjDhd5NigQ>?		MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOZNEiwJINmdGy\|LDDJR\|UxRTJwMjFOwG0>	Ml:wNVc{ODN2MkG=
human 639-V cell	NWnTW4x{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWrCbmtzUW6qaXLpeIlwdiCxZjDoeY1idiB4M{mtWkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOjd3M{eg{txO	MUPTRW5ITVJ?
human Hs-578-T cell	MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MojJTY5pcWKrdHnvckBw\iCqdX3hckBJey13N{itWEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOjd5OUmg{txO	NUHrXHc{W0GQR1XS
human UM-UC-3 cell	MkH1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXTYRoRFUW6qaXLpeIlwdiCxZjDoeY1idiCXTT3VR{0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XoxvJygTWM2OD1{LkezPVM3KM7:TR?=	NUPDS5VoW0GQR1XS
human BPH-1 cell	NWq3SlZpT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYjJcohq[mm2aX;uJI9nKGi3bXHuJGJRUC1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj65O\|Q2PSEQvF2=	NGDSVI1USU6JRWK=
human 5637 cell	NUjSeJA{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NH\YeXRKdmirYnn0bY9vKG:oIHj1cYFvKDV4M{egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlA5PTN{IN88US=>	NVnqbHFCW0GQR1XS
human 8-MG-BA cell	NVjy[Yp5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MkDWTY5pcWKrdHnvckBw\iCqdX3hckA5NU2JLVLBJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZnwxIxiSVO1NF0{NjF2MES5JO69VQ>?	MUPTRW5ITVJ?
human HCT116 cells	MmnBR5l1d3SxeHnjxsBie3OjeR?=	MWS1JIRigXN?	NEPDO4pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhPSCmYYnzJIJ6KE2WUzDhd5Nige,:jDDJR\|UxRTNwMjFOwG0>	MmLlNlI{OjZzNki=
human LB1047-RCC cell	Mn3yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXn4SWc6UW6qaXLpeIlwdiCxZjDoeY1idiCOQkGwOFcuWkOFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz6yN\|UxOSEQvF2=	M3LYdHNCVkeHUh?=
human KOSC-2 cell	NIjYdoZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MknZTY5pcWKrdHnvckBw\iCqdX3hckBMV1OFLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlQ1PjZ4MjFOwG0>	MWnTRW5ITVJ?
human COR-L88 cell	M2\xRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkSyTY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEi4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{41PzV6MzFOwG0>	MmTxV2FPT0WU
human PSN1 cell	M4e0UWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFPL[3BKdmirYnn0bY9vKG:oIHj1cYFvKFCVTkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlExQDB3IN88US=>	NGO3N41USU6JRWK=
human LXF-289 cell	Mk\VS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXHsRnNmUW6qaXLpeIlwdiCxZjDoeY1idiCOWF[tNlg6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5{MUe2JO69VQ>?	MXXTRW5ITVJ?
human MN-60 cell	MnWwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NULwN5ByUW6qaXLpeIlwdiCxZjDoeY1idiCPTj22NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOzd4MkOg{txO	M4HDOXNCVkeHUh?=
human NEC8 cell	NET1eFJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MYrJcohq[mm2aX;uJI9nKGi3bXHuJG5GSzhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkS3NFc3KM7:TR?=	M{P5WXNCVkeHUh?=
human SJSA1 cells	M1;DTnBzd2yrZnXyZZRqd25iYYPzZZk>		MWnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOMU1GxJINmdGy\|LDDJR\|UxRTRwNUWg{txO	M{\SZVE4OzB\|NEKx
human NCI-H2405 cell	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M17qSmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyOFA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC55NES5N{DPxE1?	M2fRZnNCVkeHUh?=
human YH-13 cell	NE\TXmpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MkPWTY5pcWKrdHnvckBw\iCqdX3hckB[UC1zMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuO\|U4PzZizszN	M1nQTHNCVkeHUh?=
human SK-MEL-2 cell	NG\UW3JIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MlLOTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvODl4M{Kg{rxu	NFzkbWFUSU6JRWK=
human NB13 cell	MnP3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkjmTY5pcWKrdHnvckBw\iCqdX3hckBPSjF\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT6zNlc5PiEQvF2=	MVvTRW5ITVJ?
human GAMG cell	MnPhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEDmUFNKdmirYnn0bY9vKG:oIHj1cYFvKEeDTVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM4OTVizszN	M3Hp[3NCVkeHUh?=
human NCI-H1792 cell	M1;SPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFXZ[pdKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVc6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwNEe5OVQh\|ryP	MYDTRW5ITVJ?
human KP-4 cell	Mo\yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NIDXflFKdmirYnn0bY9vKG:oIHj1cYFvKEuSLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlY6QDJ\|IN88US=>	NFz0V4JUSU6JRWK=
human HGC-27 cell	M4XId2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{HJZmlvcGmkaYTpc44hd2ZiaIXtZY4hUEeFLUK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU44OzB5NzFOwG0>	M{njRnNCVkeHUh?=
human GCT cell	NWm4b\|hCT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NEPHV4dKdmirYnn0bY9vKG:oIHj1cYFvKEeFVDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuPFUyOjFizszN	NEHaUWFUSU6JRWK=
human PFSK-1 cell	Mom0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NG\EeGpKdmirYnn0bY9vKG:oIHj1cYFvKFCIU1utNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQDZzNkig{txO	Mom3V2FPT0WU
human A172 cell	NGPGVoRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M{W2OGlvcGmkaYTpc44hd2ZiaIXtZY4hSTF5MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuPVA4QSEQvF2=	MUXTRW5ITVJ?
human HO-1-N-1 cell	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUTP[HVYUW6qaXLpeIlwdiCxZjDoeY1idiCKTz2xMW4uOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwOUW0NlUh\|ryP	M2ftNnNCVkeHUh?=
human HN cell	NHjBdm9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUXJcohq[mm2aX;uJI9nKGi3bXHuJGhPKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS57N{C5O{DPxE1?	Mn;xV2FPT0WU
human IST-MES1 cell	MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVnYTlVPUW6qaXLpeIlwdiCxZjDoeY1idiCLU2StUWVUOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwOUe1NlEh\|ryP	NWLQTYFPW0GQR1XS
human TGW cell	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVTJcohq[mm2aX;uJI9nKGi3bXHuJHRIXyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTZwMEW2PFIh\|ryP	NVHMNItLW0GQR1XS
human COR-L23 cell	M{PXNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mo\jTY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEKzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4{PzN3IN88US=>	NWfNflF{W0GQR1XS
human D-566MG cell	NFLHTW1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NWP4XHM5UW6qaXLpeIlwdiCxZjDoeY1idiCGLUW2Om1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi55OEi3N{DPxE1?	MnHPV2FPT0WU
human SKG-IIIa cell	NFTQRXFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXjJcohq[mm2aX;uJI9nKGi3bXHuJHNMTy2LSVnhJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok45PTV5MjFOwG0>	MVPTRW5ITVJ?
human NCI-H446 cell	MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MnLDTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSES0OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvODF6MTFOwG0>	NFvwRYlUSU6JRWK=
human KYSE-270 cell	NYqyfmlkT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NYXWNoxDUW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVI4OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTdwMEO4O\|Ih\|ryP	MkLlV2FPT0WU
human CAL-39 cell	NVS1V\|hET3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NUHjPI9{UW6qaXLpeIlwdiCxZjDoeY1idiCFQVytN\|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjN3MkSg{txO	MWXTRW5ITVJ?
human IST-SL1 cell	NGDaUoVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1THfmlvcGmkaYTpc44hd2ZiaIXtZY4hUVOWLWPMNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvPDN\|NEmg{txO	Mly4V2FPT0WU
human SF539 cell	Mo\FS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NE\Yc45KdmirYnn0bY9vKG:oIHj1cYFvKFOINUO5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{42PTF7NzFOwG0>	NG\UXlJUSU6JRWK=
human TE-1 cell	NYDKfnhKT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1;n[2lvcGmkaYTpc44hd2ZiaIXtZY4hXEVvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUeuPFkxQTFizszN	NVTncod5W0GQR1XS
human NB10 cell	M{PkVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUfJcohq[mm2aX;uJI9nKGi3bXHuJG5DOTBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15Lkm4O\|U5KM7:TR?=	MnLyV2FPT0WU
human 8505C cell	NF\y[mlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVHJcohq[mm2aX;uJI9nKGi3bXHuJFg2ODWFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nz65PVgyPyEQvF2=	NF;idGJUSU6JRWK=
human DB cell	MmmyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NW\hcGhuUW6qaXLpeIlwdiCxZjDoeY1idiCGQjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUiuNFEyOzFizszN	MmTsV2FPT0WU
human NCI-H28 cell	NIL6PWhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3jKRWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVgvPTl6OESg{txO	NEK3PHlUSU6JRWK=
human LOXIMVI cell	MkTQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MonaTY5pcWKrdHnvckBw\iCqdX3hckBNV1iLTW\JJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PE43OzdyMTFOwG0>	NVn6enM{W0GQR1XS
human ME-180 cell	M2jRfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mn:zTY5pcWKrdHnvckBw\iCqdX3hckBOTS1zOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlgxOzl3IN88US=>	M3;6VHNCVkeHUh?=
human ES3 cell	M2fzOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlywTY5pcWKrdHnvckBw\iCqdX3hckBGWzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD17LkGyO\|k1KM7:TR?=	MWrTRW5ITVJ?
human SK-N-FI cell	MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFHIPHpKdmirYnn0bY9vKG:oIHj1cYFvKFONLV6tSmkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06NjRzNkm5JO69VQ>?	NGXITVlUSU6JRWK=
human NBsusSR cell	NETkXIhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mlv3TY5pcWKrdHnvckBw\iCqdX3hckBPSnO3c2PSJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVAvOjNzODFOwG0>	M{LBfXNCVkeHUh?=
human MCF7 cell	MlPES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVfJcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMT6xPFQ6KM7:TR?=	NHjobmtUSU6JRWK=
human A549 cell	M1LMcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVHJcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMT6yNFYh\|ryP	NYq4bmhRW0GQR1XS
human HuP-T4 cell	MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MoPqTY5pcWKrdHnvckBw\iCqdX3hckBJfVBvVESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNE41OjdzIN88US=>	NYjEWJZbW0GQR1XS
human HSC-2 cell	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NWXGdmllUW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyNDd6NEKg{txO	MoLvV2FPT0WU
human A253 cell	NV33S4pxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXTJcohq[mm2aX;uJI9nKGi3bXHuJGEzPTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zNT6yPFM1KM7:TR?=	MYjTRW5ITVJ?
human HCT-116 cell	NEXCbZRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NEXGd5hKdmirYnn0bY9vKG:oIHj1cYFvKFCFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xPE4xODR\|IN88US=>	M3\hdnNCVkeHUh?=
human HCT-116 cell	MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MojlTY5pcWKrdHnvckBw\iCqdX3hckBJS1RvMUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVkvPjZ6IN88US=>	M4XGSnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Protocol

Kinase Assay:^[1]	+ Expand CDK assay: The activity of CDK1 cyclin B1, CDK1 cyclin A, CDK2 cyclin E, and CDK4 cyclin D is measured by a homogeneous time-resolved fluorescence assay in a 96-well format. The assay buffer contained 25 mM Hepes, 6.25 mM MgCl2, 0.003% Tween 20, 0.3 mg/mL BSA, 1.5 mM DTT, and ATP as follows: 162 μM (CDK1), 90 mM (CDK2), or 135 μM (CDK4). CDK1 and CDK2 buffer contained 10 mM MgCl2. Test compounds are diluted in assay buffer to 3-fold their final concentration in 20 μL, and the reaction is started by the addition of a 40 μL assay buffer containing the pRB substrate (0.185μM). The plates are incubated at 37°C for 30 min with constant agitation, and the reaction is terminated by the addition of 15 μL of 1.6μM anti-phospho pRB antibody (Ser-780) in 25 mM Hepes, 24 mM EDTA, and 0.2 mg/mL BSA. After an additional 30 min of incubation with shaking, 15μL of 3nM Lance-Eu-W1024-labeledanti-rabbitIgG and 60 nM Alophycocyanin-conjugated anti-His-6 antibody in 25 mM Hepes, and 0.5 mg/mL BSA is added and incubated for 1 h. The plates are read in the Victor-V multi- label reader at excitation 340 nm and emission 615 nm and 665 nm. The IC50 values are calculated from the readings at 665 nm and normalized for Europium readings at 615 nm. Ki values are calculated according to the equation: Ki= IC50/(1 + S/Km ), where S is the ATP concentration in the assay and Km is the Michaelis-Menten constant for ATP. The inhibitory activity against the panel of kinases is determined by the IMAP assay technology.
Cell Research:^[3]	+ Expand Cell lines: MDA-MB-231 cell line Concentrations: 20 μM Incubation Time: 72 h Method: Log phases cells (25,000) are seeed in 96-well plates and incubated in a 37℃ incubator with CO2, After 24 h, different concentrations of RO-3306 are administered to determine the drug concentrations required to achieve a 50% growth inhibition (IC50). MTT (20 μL, 5mg/mL stock solution in saline) is added to each well and the cells are incubated for 4 h. Supernatants are removed and formazan crystals from viable cells are solubilized with 200 μL anhydrous DMSO. The absorbance is detected with a 550 model microplate reader at the 565 nm wavelength. (Only for Reference)

Kinase Assay:^[1]

+ Expand

CDK assay:

The activity of CDK1 cyclin B1, CDK1 cyclin A, CDK2 cyclin E, and CDK4 cyclin D is measured by a homogeneous time-resolved fluorescence assay in a 96-well format. The assay buffer contained 25 mM Hepes, 6.25 mM MgCl2, 0.003% Tween 20, 0.3 mg/mL BSA, 1.5 mM DTT, and ATP as follows: 162 μM (CDK1), 90 mM (CDK2), or 135 μM (CDK4). CDK1 and CDK2 buffer contained 10 mM MgCl2. Test compounds are diluted in assay buffer to 3-fold their final concentration in 20 μL, and the reaction is started by the addition of a 40 μL assay buffer containing the pRB substrate (0.185μM). The plates are incubated at 37°C for 30 min with constant agitation, and the reaction is terminated by the addition of 15 μL of 1.6μM anti-phospho pRB antibody (Ser-780) in 25 mM Hepes, 24 mM EDTA, and 0.2 mg/mL BSA. After an additional 30 min of incubation with shaking, 15μL of 3nM Lance-Eu-W1024-labeledanti-rabbitIgG and 60 nM Alophycocyanin-conjugated anti-His-6 antibody in 25 mM Hepes, and 0.5 mg/mL BSA is added and incubated for 1 h. The plates are read in the Victor-V multi- label reader at excitation 340 nm and emission 615 nm and 665 nm. The IC50 values are calculated from the readings at 665 nm and normalized for Europium readings at 615 nm. Ki values are calculated according to the equation: Ki= IC50/(1 + S/Km ), where S is the ATP concentration in the assay and Km is the Michaelis-Menten constant for ATP. The inhibitory activity against the panel of kinases is determined by the IMAP assay technology.

Cell Research:^[3]

+ Expand

Cell lines: MDA-MB-231 cell line
Concentrations: 20 μM
Incubation Time: 72 h
Method: Log phases cells (25,000) are seeed in 96-well plates and incubated in a 37℃ incubator with CO2, After 24 h, different concentrations of RO-3306 are administered to determine the drug concentrations required to achieve a 50% growth inhibition (IC50). MTT (20 μL, 5mg/mL stock solution in saline) is added to each well and the cells are incubated for 4 h. Supernatants are removed and formazan crystals from viable cells are solubilized with 200 μL anhydrous DMSO. The absorbance is detected with a 550 model microplate reader at the 565 nm wavelength.
(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	13 mg/mL warmed (36.98 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Ro-3306 SDF

Molecular Weight	351.45
Formula	C₁₈H₁₃N₃OS₂
CAS No.	872573-93-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

CDK Signaling Pathway Map

Related CDK Products

SU9516 ^New

SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.
Purvalanol A ^New

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.
AT7519 HCl ^New

AT7519 HCl is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM in cell-free assays. It is less potent to CDK3 and little active to CDK7. Phase 2.
Palbociclib (PD-0332991) HCl

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
Dinaciclib (SCH727965)

Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.
Flavopiridol HCl

Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.
Roscovitine (Seliciclib,CYC202)

Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
abemaciclib mesylate (LY2835219)

abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Ribociclib (LEE011)

Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.

Choose Your Country or Region

By Signaling Pathways

By product type

Ro-3306

Cited by 4 Publications

3 Customer Reviews

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Ro-3306 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

CDK Signaling Pathway Map

Related CDK Products

Choose Your Country or Region

By Signaling Pathways

By product type

Ro-3306

Cited by 4 Publications

3 Customer Reviews

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Ro-3306 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

CDK Signaling Pathway Map

Related CDK Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)